Remembering Dr. Craig Leonardi
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
IPC Councilor José-Manuel Carrascosa Carrillo, MD, PhD, on the BeNeBio trial and whether dose reduction fits an era focused on disease modification.
What happened in psoriasis at the 2026 EADV Congress? IPC shares highlights from its symposium on personalized medicine, as well as psoriasis sessions and late-breaking research from Vienna.
World Psoriasis Day, observed each year on October 29, was launched by the International Federation of Psoriasis Associations (IFPA) in 2004 to give a voice to the more than 125 million people worldwide living with psoriasis and psoriatic arthritis. To mark this year’s observance, IPC joined the Latin American Society of Psoriasis and Dermoimmunology (SOLAPSO) and the Skin Inflammation and Psoriasis International Network (SPIN) to create a video series around the theme “Look Beyond My Skin,” featuring voices from all three organizations. Missed the videos on social media? Watch the full series on the IPC YouTube channel.
Take Two with IPC gives a longer presentation a second life in two minutes. Each video takes an expert talk IPC has already published (a Take Ten recording or a symposium presentation) and condenses the clinical substance. The series launched this month alongside the World Psoriasis Day campaign with four videos on pediatric psoriasis: Psoriasis Look-Alikes and Anti-TNF-α Induced Skin Eruptions with IPC Board Member Amy Paller, MS, MD; Conventional Therapies with IPC Councilor Mona El-Kalioby, MBBCh, MSc, MD; and Phototherapy in Pediatric Psoriasis with Fernando Valenzuela, MD. New Take Two videos will be featured each month, drawn from the Take Ten with IPC library and recordings from IPC symposia, with a link to the full presentation for each.
Select presentations from the Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum, hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the 55th Annual European Society for Dermatological Research (ESDR) Meeting, are now available. Topics include disease endotypes, atopic dermatitis-psoriasis overlap, cardiovascular risk in psoriasis, and genetic susceptibility.
In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in psoriasis, why these distinctions matter, what current research tells us, and which areas should be prioritized in future psoriasis research.
Commentary: COVID-19 consensus study in Spain
Lluís Puig, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
PUBLICATION
COMMENTARY
The COVID-19 pandemic has disrupted many aspects of social behavior and medical practice. The flow of information on the different manifestations of the disease is bewildering, with more than 9,500 publications in just four months, many of them freely available.
The dermatological aspects of the disease (apart from occupational dermatitis) were revealed when dermatologists became involved in care of COVID patients, and soon cases pervaded social media.
The pandemic, which at the time of this writing has affected close to 250,000 in Spain, causing close to 26,000 deaths, struck Madrid first and then Barcelona in full force on early March. A “state of alarm” was declared in Spain on March 14. In both cities, dermatological consultations in most hospitals were shut down. All the available dermatology residents and most staff below age 60 were redeployed to COVID wards, which made up 80% of the available beds. The ICUs tripled their capacities and field hospitals were set up, including a 1500-bed facility in Madrid Exhibition Halls.
At that time, Dr. Alba Català (a dermatologist at Hospital Plató, serving a population of 135,000 in uptown Barcelona) and Dr. Cristina Galván Casas (working at Hospital Universitario de Móstoles, serving a population of 168,000 in the periphery of Madrid) were attending to COVID-19 patients full time. The two were struck by the dermatological manifestations which were starting to be noted in COVID-19 cases. Since no publications on skin symptoms in COVID-19 were available, Català and Galván Casas joined an online dermatology chat group to understand the issue better. From there, they decided to launch a survey, designing the protocol, and navigating the red tape, with the help of Dr. Gregorio Carretero (Hospital Universitario de Gran Canaria, which serves a population of 350,000).
With the support of the Spanish Academy of Dermatology and Venereology (AEDV), an amazing feat of collaboration started: in the first 2 weeks of April, 100 dermatologists working on the front line of COVID care contributed 430 documented cases of dermatological manifestations, of which 375 with confirmed or suspected COVID-19 made the cut. With the support of the Research Unit of the AEDV, a consensus was reached, and a landmark paper with a comprehensive clinical categorization of the skin manifestations of COVID was published in the British Journal of Dermatology, with an exhaustive companion atlas as an online supplement.
This is an exhilarating example of teamwork and generous collaboration of dermatologists from all ranks who worked long shifts at COVID-19 wards, switching PASI for PAFI. Busy days with varying supplies of personal protective equipment, phones in polyethylene bags, sleepless nights, and perhaps some contagion were perhaps worth the effort. Kudos and thank you.
Disclaimer: Views expressed in this commentary are those of the author and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.
Categories
Recent Posts
Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?
Remembering Dr. Craig Leonardi
Meet IPC’s Newest Councilors: Psoriasis Experts from Europe, Asia, and Africa
Also Read
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
Prioritizing the Patient Perspective in Psoriasis Care and Communications
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Revised IPC Statement on COVID-19
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
Subscribe to the IPC Newsletter